Skip to main content
Caplight Logo









Comanche Biopharma

Comanche Biopharma

Private
Concord, MassachusettsHealthcare & Life Scienceshttps://comanchebiopharma.com/

Last Round

VC Round

Jan 5, 2026

Total Funding Raised

$111.1M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Comanche Biopharma is a biopharmaceutical company developing an investigational siRNA medicine for preterm preeclampsia.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

siRNA therapeuticssmall interfering RNApreeclampsia treatmentsFlt1preterm preeclampsiabiotech startupclinical-stage biotechprecision medicineorphan drugdrug developmentRNA interferenceRNAiclinical trialsbiopharmamaternal health

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Comanche Biopharma Comparables

Compare Comanche Biopharma with similar companies based on industry and business-model similarity.

Comanche Biopharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
MirZyme Therapeutics
86%
DiaMedica Therapeutics Inc.
67%
Evergreen Therapeutics, Inc.
63%

Comanche Biopharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundJan 5, 2026
Series BJan 17, 2024
Series AJun 28, 2021

Key People

Founding team and executive leadership

Thomas P. Hess

Chief Financial Officer

Executive Team

Belen Vicente Blazquez

Chief Operating Officer

Executive Team

Comanche Biopharma Investors

Notable investors and investment history

Comanche Biopharma investors
InvestorRounds
GVSeries A, VC Round, Series B
New Enterprise Associates (NEA)VC Round, Series B
F-Prime CapitalSeries A, Series B
Longview Healthcare VenturesSeries A, VC Round, Series B
F-Prime CapitalVC Round, Series B, Series A
Lilly Asia VenturesSeries A, VC Round, Series B
Atlas VentureVC Round, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 7, 2026

    Open roles increased to 10, doubling the trailing average.

  • Aug 22, 2026

    Monthly visitors grew 72% MoM, reaching 3K.

Comanche Biopharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Comanche Biopharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Comanche Biopharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersConcord, Massachusetts
Employee Range27
Year Founded2020
Last FundingJan 5, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?